HDAX Therapeutics
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
333 Bay St Ste 2400, Toronto, Ontario, M...Website
www.hdaxtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About HDAX Therapeutics
HDAX Therapeutics's entrepreneurial drug developers have built the technology behind HDAX from a mere concept into distinct programs with therapeutical potential in neurology, cardiometabolic diseases and more. HDAX is well-charged with an extensive network, profound passion and unwavering tenacity to transform therapeutic outcomes for patients. HDAX exists to deliver meaningful medicines for patients. HDAX Therapeutics recognize the challenges with current HDAC6 targeting strategies, and are fundamentally reconceptualizing the way it is approached to unlock its full therapeutic potential and revolutionize patient outcomes. HDAX Therapeutics's values serve as HDAX Therapeutics's inspiration to excel in HDAX Therapeutics's endeavours and never lose sight of why HDAX Therapeutics's work matters to change patients lives.Explore more
HDAX Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HDAX Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on HDAX Therapeutics recently announced quarterly report
Product Launch: Get notified when HDAX Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at HDAX Therapeutics
Check if HDAX Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once HDAX Therapeutics has new funding data
Check out if HDAX Therapeutics is spiking on competitors!
HDAX Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if HDAX Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to HDAX Therapeutics
Compare insights from companies similar to HDAX Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$5.4M
11-50
Private
$230M
-
DD
D. Michael DixonChief Financial Officer and Chef De La Direction Financière
Company Profile Activity
Activity Insights
HDAX Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HDAX Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HDAX Therapeutics.
HDAX Therapeutics financials insights
Gather financial insights about HDAX Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Angel/Seed
$3.2M
HDAX Therapeutics Tech Stack
A closer look at the technologies used by HDAX Therapeutics
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Executive Move
Board of Directors
Executive Move
Board of Directors
HDAX Therapeutics News & Media
HDAX Therapeutics Announces First Closing of Oversubscribed US $3.2 (CA $4.3) Million ...
TORONTO, September 05, 2024--HDAX Therapeutics ("HDAX"), a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and development of breakthrough therapeutics for high unmet medical needs, announced the first closing of an oversubscribed US$3.2 (CA$4.3) million seed round. The financing was led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners ("TIAP"), with participation from Eos Bioinnovation ("Eos"), Ontario Centre of Innovation ("OCI"), and othHDAX Therapeutics Announces First Closing of Oversubscribed US $3.2 (CA $4.3) Million Seed Financing
TORONTO--(BUSINESS WIRE)--HDAX Therapeutics (“HDAX”), a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and development of breakthrough therapeutics for high unmet medical needs, announced the first closing of an oversubscribed US$3.2 (CA$4.3) million seed round. The financing was led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners (“TIAP”), with participation from Eos Bioinnovation (“Eos”), Ontario Centre of Innovation (“OCI”), and otherHDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORS
Appointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding HDAX Therapeutics
Sign Up For FreeTo access detailed company insights
HDAX Therapeutics's entrepreneurial drug developers have built the technology behind HDAX from a mere concept into distinct programs with therapeutical potential in neurology, cardiometabolic diseases and more. HDAX is well-charged with an extensive network, profound passion and unwavering tenacity to transform therapeutic outcomes for patients. HD... Read More
